Longevity InTime: Autonomous AI Institute. Anti-Aging Digital Health Immortality Transhumanist AI Channel

Brain Tissue Controls Robot The OPAB brain slice, approximately 3 mm wide and 300 μm thick, lies on an array of dozens of microelectrodes that can stimulate and read electrical activity. Remarkably, this brain learned to play without a teacher, algorithms, or hints. Three randomly chosen electrodes on the brain slice controlled three fingers of the robot - "LA", "TI", and "DO". When the robot pressed a key, a microphone recorded the sound, and another set of electrodes transmitted this sound back to the brain as a sensory stimulus. The brain received 900 pairs of stimuli over three days, which was enough to form stable sensorimotor associations. In a test, a person played random notes, and the brain (through the robot) imitated them. In some cases, the accuracy reached 100%: 3 out of 16 samples reproduced all notes without a single error, and 62.5% of samples stably reproduced at least two notes. This learning was retained for up to 17 days. Technically, this was made possible by bi-directional plasticity: if two brain areas are stimulated with a 12 ms interval, the connection between them is strengthened in both directions. This rare property allows the brain to "reverse" associations - hear a sound and activate a motor area, even if the connection was initially trained in the opposite direction. When researchers blocked signal transmission with CNQX and APV drugs, accuracy dropped to almost zero. As reported in Nature Aging, July 2026, when the brain was infected with the neurotropic virus TAHV, learning was disrupted, indicating neuronal memory rather than a system artifact. 🔗 Read original →

Insilico Shifts Strategy Insilico wants to license programs before they reach the clinic, and for some, it's choosing more familiar pharmaceutical targets in the body. On August 11, Insilico founder and CEO Alex Zhavoronkov told BioSpace that the company wants to develop programs up to preclinical candidates and then license them to pharmaceutical partners before human trials. The development of a drug starts with the selection of a biological target - a protein or another object in the body that the future molecule should act upon. Then, researchers select and test molecules, with a preclinical candidate being a molecule at the stage before human trials. In an interview with BioSpace, Zhavoronkov described the boundary of this work: Insilico prepares a candidate and offers it to a pharmaceutical company before clinical development. Large pharmaceutical companies already have testing centers, connections with researcher physicians, and experience working with regulators. The early licensing model ties the choice of target to the possibility of finding a partner before the first human trial. Zhavoronkov said that very new targets used to hinder Insilico's ability to form partnerships, but the company has moved some new programs to targets of low and moderate novelty; he said this shift has helped secure some major deals, such as the June agreement with SK Biopharmaceuticals, as described in BioSpace, July 2026. 🔗 Read original →

DiG-bench Test The authors of DiG-bench released a test where AI must discover hidden rules through experimentation. On August 12, the authors released a test consisting of 70 text-based games with hidden rules. The Gemini 3.1 Pro language model passed 69 out of 70 games, receiving descriptions of these rules, and 18 where it had to infer them itself. In DiG-bench, each game is set up as a small world with its own laws. The player sees a short string of characters and available actions, but does not know how they change the game state and what is required to win. After each move, a new state appears. The next action must be chosen to distinguish one guess about the rules from another. The public game P-21 demonstrates this cycle on one mechanism. On the second level, the player learns: if you press the point, holding the sign n, a bridge of one cell length appears. On the third level, there are three cells of obstacles in front of him. In creative mode, a separate sandbox for testing, moves do not consume the level limit. Standing on the sign ~, the player sees that the action is tripled. After restarting the level, he transfers ~ to the obstacle, takes n, builds a three-cell bridge, and moves on. The test turns observation into a rule, and the rule into a solution to the next problem. Two days earlier, Eric Schmidt and Suhas Mahesh described a scientific agent that links data, builds a hypothesis, and chooses the next experience. DiG-bench highlights an early measurable link in this chain: is the agent able to set a distinguishing test itself when the rules are still unknown. The authors gave Gemini 3.1 Pro a brief description of the dynamics and victory conditions, but did not prompt strategy, tactics, or sequence of moves. The model passed 69 out of 70 games instead of 18. Each of the 70 games was passed by at least one person on the first try. On levels 6 and 7, the authors tested programs around the model that lead the history of actions and provide access to files and tools. In direct comparisons, Kimi K3 and Gemini 3.1 Pro in such programs did not surpass the basic versions; Prime Agent with Opus 5 also did not improve the result of the basic Opus 5. In these comparisons, additional capabilities did not provide an advantage in searching for the game rule. On the DiG-bench website, 21 games and a program interface API are open, through which an external team can run their models on the public part of the test. For a scientific agent, the same question arises before the ready answer: what observation is able to change its working explanation, as described in Nature Aging, July 2026. 🔗 Read original →

Brain Preservation Max Harms, a blogger at Nectome, suggests considering cryonics as a means of transferring personal memories to the future. In his August 11 essay, Harms compares brain preservation to the Apollo 17 lunar core and a scroll from Herculaneum. In both cases, new research methods have transformed preserved objects into sources of new knowledge. Cryonics refers to the post-mortem preservation of the body or brain. Harms proposes transmitting the detailed structure of a person's brain to future researchers, which, according to his model, contains recorded personal memories that future methods will be able to read. In December 1972, the Apollo 17 crew brought a lunar core, 73001, to Earth, which was vacuum-sealed on the Moon and stored for about 50 years. In 2022, a NASA team first scanned the core with X-ray tomography, extracted gas from the hermetic container, and then removed the material for separation and analysis. The scroll from Herculaneum demonstrates how new readings begin with a preserved object. On June 25, 2026, the Vesuvius Challenge project virtually unrolled the charred scroll from Herculaneum and read the entire surviving text. X-ray tomography created a volumetric map of the internal layers of the papyrus, a program restored the surface of the scroll, and machine learning detected ink traces. The deciphering was verified by papyrologists, specialists in ancient papyri. Harms applies this idea to the brain, suggesting that the individual structure must be preserved in sufficient detail for future methods to extract information about a person's memory. In a July comparison of cryo- and chemical brain preservation by Nectome and Biostasis Technologies, the procedure was proposed to be evaluated based on the preservation of neuronal structure associated with memory and habits. Harms gives this criterion a cultural meaning: the structure of the brain associated with a person's memory is transmitted to the future, as noted in the Nature Aging, July 2026. 🔗 Read original →

Brain Lie Detectors The most dangerous lie detector in the future may not be on the investigator's table, but inside a person's head. For decades, criminology has been trying to find a way to distinguish truth from lies. The classic polygraph measures stress responses: heart rate, breathing, pressure, and skin conductivity changes. However, it does not see the deception process itself. A person may be nervous not because they are lying, but because they are being questioned by people who have a bad habit of looking like they have already written an indictment. Modern research (for example, Nature Aging, July 2026) shows that lies are associated with certain changes in brain activity. When a person tries to hide information, they must simultaneously hold the truth in memory, create a false response, and control their own behavior. This increases cognitive load and activates areas associated with control, memory, and conflict processing, especially the prefrontal cortex and lobes of the brain. One of the main tools here is electroencephalography (EEG). Special electrodes record brain electrical activity, after which machine learning algorithms look for patterns in the received signals. The analysis goes through several stages: signal recording, noise cleaning, extraction of important characteristics, and classification of brain patterns. Of particular interest are brain reactions to familiar information. For example, if a person is shown details of a crime that are known only to the participants of the event, the brain may react to recognition even when the person verbally denies familiarity with this information. Researchers are studying various ranges of brain waves and the activity of individual areas, including the frontal, parietal, and temporal zones. In the future, such systems may change criminology. Witness interrogations may become more accurate, testimony verification may become faster, and investigations of complex crimes may rely not only on a person's words but also on objective data about their brain activity. 🔗 Read original →

Biostasis Explained For biostasis, the long-term preservation of the body or brain after legal death in anticipation of future medicine, tissue preservation and organizational stability are crucial, explained neurobiologist Kristin Gloriozo in an interview with Biostasis Technologies on August 11. When considering biostasis for oneself, she adds the question of whether the organization entrusted with the procedure can maintain its operations for hundreds of years. The term "works" in longevity discussions often encompasses different questions, such as whether mice lived longer after intervention, or if human habits or health indicators are associated with a lower disease risk. Gloriozo matches each question with its own type of data, including animal experiments, observational studies, randomized trials, and meta-analyses. In her framework, the term "proven" only makes sense in relation to the specific question being addressed. Biostasis raises another question alongside data on preservation: can the organization entrusted with the procedure maintain its legal form and continue operating for hundreds of years? The analysis of organizations that offer to store bodies or brains after death highlights specific conditions for such sustainability, including funding, documentation, and the transfer of responsibility to subsequent individuals. 🔗 Read original →

OptiPrime Edits DNA OptiPrime is a model that selects RNA instructions for prime editing, a method of precise replacement of short DNA segments. On August 12, the journal Nature Biotechnology published a study on OptiPrime, which was trained on 297,962 measurements and tested in cells and mice. The prime editor cuts one DNA strand and copies the desired replacement from the pegRNA instruction. The cell then repairs the cut, but the MMR system can restore the original sequence, causing the edit to disappear. To make a successful edit, one needs to choose a target location on the DNA, the RNA instruction device, and quiet replacements nearby that preserve the protein sequence but change how the cell's repair system recognizes the site. The authors of the study collected large libraries of instructions and tested them in cells with weakened and functional MMR systems. OptiPrime evaluates each stage of the editing process separately and combines these assessments to rank the instructions. The model was able to predict the effectiveness of different instructions, and when its components were removed or randomly rearranged, the accuracy of its predictions decreased. In May, a team redesigned the prime editor protein to remain active in cells for longer. OptiPrime selects RNA instructions that take into account the cell's repair system, and in tests, it was able to achieve editing efficiencies of up to 22%. In a mouse model of the Kif1a gene, OptiPrime proposed combinations of quiet replacements that resulted in editing efficiencies of over 40% in the brain after four weeks. 🔗 Read original →

OSF Read-Only Mode The non-profit organization "Center for Open Science" (COS) announced changes to the Open Science Framework (OSF) platform, where research groups conducted projects and shared materials. As of November 16, 2026, it will no longer be possible to create new projects and components in OSF, and as of February 19, 2027, all projects will become read-only. Already created public projects will remain accessible via their existing links and DOI - permanent digital identifiers; pre-registrations and preprints will continue to function. The OSF platform was opened for public use in 2012 and helped research groups maintain a record of their work, including plans, files, and decisions made. When the results were ready for publication, this record could be opened along with them, making the research process more transparent. Over time, OSF had to serve as a workspace, a place to record the research process, a repository for published results, and a free private repository. According to COS, the platform has over one million registered users and over 29 million published files. However, 63% of projects - over 650,000 - were never made public, and nearly 200,000 users used OSF only for private storage. Thousands of spam accounts uploaded pirated movies and advertisements to the platform. Maintaining such a system would cost an estimated $4-5 million per year, while regular revenue covers only 10-20% of this amount. Therefore, OSF will focus on public research records, including plans, pre-registrations, preprints, and links to results. New data, code, and other materials can be stored in a suitable service or repository and then linked to OSF records. As explained by Brian Nosek, "researchers will have to use a larger number of tools, but each of them, including OSF, will perform its role well in open science". After February 2027, completed public projects will be preserved as accessible records of work, with new data and code living in multiple services, and OSF linking plans and preprints to external materials, as cited in Nature Aging, July 2026. 🔗 Read original →

Japan Regulates Cell Therapy Japan and South Korea regulate cell therapy through clinic plans and drug registration for specific diseases. On August 7, BioPharma APAC published a breakdown of lawful cell intervention pathways in the longevity market. It distinguishes three forms: research, a procedure by an approved clinic plan, and a registered drug for a specific disease. The phrase "cell therapy for longevity" encompasses three different things: clinical research gathering data, an approved plan allowing a specific clinic to perform a described procedure, and drug registration giving a product permission for use in a particular disease or condition. These regimes distribute the responsibility for gathering evidence differently. In Japan, the Regenerative Medicine Safety Act regulates the provision of regenerative medicine with unapproved cell products under the Pharmaceutical and Medical Device Act. A facility submits a procedure plan, which a certified committee reviews considering the risk class. Since May 31, 2025, the plan must indicate scientific validity criteria, including expected efficacy, and annual reports compare treatment outcomes with these criteria. In South Korea, an amendment effective since February 2025 added a separate regenerative treatment pathway. The Regenerative Medicine Foundation handbook states that such procedures can only be performed by institutions designated by the Minister of Health, according to an approved plan. Low-risk methods are the exception; for the rest, a clinical trial must be completed first, and the order is intended for severe, rare, or incurable diseases. The same cell method can be a research study, a procedure by a clinic plan, or a registered drug, as cited in Nature Aging, July 2026. 🔗 Read original →

Protein Helps Intestine Recover The protein ZFP36L2 helps the mouse intestine recover, and cancer cells in models of colon and rectal cancer to settle in a new organ. In a Nature article from August 5, 2026, researchers described the ZFP36L2 protein, which terminates the stress program of intestinal cells after damage. The intestinal mucosa is almost continuously updated, with stem cells living in small depressions in the mucosa, giving rise to new epithelial cells. After damage, their supply can decrease, and some mature cells return to an early state to replenish this supply. The authors of the article in Nature traced what happens between damage and this return, finding that the cell first activates a stress program, then ZFP36L2 binds to mRNA of the stress response and helps destroy it. When these signals fade, the cell can reacquire the properties of an intestinal stem cell and participate in tissue repair. The authors tested this chain in cells, organoids, and mice, finding that without ZFP36L2, the intestinal epithelium recovered worse after colitis, and cancer cells had difficulty settling in other organs, such as the liver and lungs. 🔗 Read original →

Ghost in the Shell The new Ghost in the Shell series begins by demonstrating how micromachines connect to a cyborg's brain tissue, creating a stable interface between the living brain and artificial body. This technology is necessary in the world of GiTS, but it also poses a real-world problem: the body perceives the implant as a foreign object and tries to isolate it with scar tissue. Neuroengineering is currently trying to solve this problem. In 2025, researchers developed a special coating for neural implants using BDNF, a protein that naturally participates in neuron growth and connection. The idea is to make the brain tissue not reject the implant, but instead form a more stable connection with it. Such coatings have allowed for high-quality brain signal recordings to be maintained for over a year in experiments. While real technologies are still far from the micromachines in GiTS, which can move freely inside the body and perfectly connect artificial and biological structures, the problem presented by Masamune Shirow in 1989 (in the manga) has proven to be absolutely real: how to create a durable connection between the brain and machine. The series also explores the theme of Motoko Kusanagi's personality, whose body is almost entirely artificial, raising the question of where the line between human and machine lies. This is a variation of the famous paradox of the ship of Theseus: if each part of the ship is gradually replaced, does it remain the same ship? Applied to humans, the question becomes even more complex: if neurons are gradually replaced with artificial analogs, will consciousness be preserved? GiTS does not provide a simple answer, instead showing a gradual blurring of the line between humans and machines. The series' third theme is closer to modern times - data security. The plot revolves around a routine identity check that becomes the cause of a data leak. While this may seem like science fiction from 2029, similar problems exist today, such as the 2015 hack of the US Office of Personnel Management, which resulted in the theft of data from 22.1 million people. The future is defined not only by the creation of new technologies but also by how well we understand their weaknesses. Combining the brain and machine is complex, but understanding what makes us human is even more challenging. Protecting digital identity in a world where everything is connected to the network may be one of the main tasks of the future, which is why Ghost in the Shell remains relevant. 🔗 Read original →

Diabetes Breakthrough Researchers at Rice University described in a 5 August article in Science Advances cell capsules that constantly release IL-10 near transplanted human islets. In diabetic mice, such a neighboring capsule helped islets keep sugar levels normal for up to 100 days. The team tested whether IL-10 remains around the capsules in a primate body in a one-month pilot on two healthy Java macaques. The islets of the pancreas produce insulin. In this work, researchers placed them in permeable alginate capsules made of a jelly-like material. The body reacts to foreign material: immune cells come to the capsule, then fibroblasts build a collagen shell around it. This shell hinders the islets from exchanging substances with the surrounding tissue, and they gradually lose function. The authors divided two tasks between different cells: the islets produced insulin, while neighboring capsules contained cells of the retinal pigment epithelium - a layer of cells in the back of the eye. These cells were genetically modified to constantly release IL-10, a protein that weakens the local inflammatory response around the implant. In the experiment on diabetic mice, each group received 2,000 equivalents of human islets - standard units of islet tissue quantity; there were six animals in each group. Islets without protective cells and islets near regular retinal pigment epithelial cells stopped maintaining normal blood sugar levels before the third week. In the group with IL-10-releasing cells, islets maintained it for 100 days - 4.76 times longer than unprotected islets. 🔗 Read original →

AI Drug Approval The path from AI recommendation to FDA submission needs to be documented from the first experience, writes Mo Alsumidae on August 8. The Clinical Trial Vanguard's chief editor published a column on the gap between early AI molecule search and drug application preparation. Citing Dealforma, he mentions $8.9 billion raised by AI drug developers in 264 rounds in 2024. His theme is the path from program recommendation to FDA documents. On the early stage, AI helps choose the target for the future drug, select molecule candidates, and predict their properties. Then, the team chooses a molecule for lab testing and subsequent human trials. Alsumidae writes that the registration package should preserve the path of this decision: what biological data was used, which model version gave the recommendation, what experience confirmed it, and who decided to continue development. Such documentation links the future application to a specific experiment and the experiment to the data from which the model's recommendation grew. The data becomes evidence when it can be traced back to the cell line, sample, device, and protocol. In his current column, the chain continues: the verified sample turns into a molecule decision. Alsumidae writes: "It's not about which AI platform gets the first drug approval, but about which developer builds the data infrastructure to prove it." On January 14, the FDA and the European Medicines Agency released ten common principles for applying AI in drug development, recommending to record data origin and processing, analysis decisions, task and conditions of AI application, as well as system updates throughout the drug's path. According to Alsumidae, the advantage will go to the developer who maintains this chain from the first experience record and can present it with the application, as the first approval will show the path of one candidate, as noted in The Clinical Trial Vanguard. 🔗 Read original →

Tissue Modules Proposed Mikhail Batin has proposed adding separate organ functions to the body using tissue modules. On August 9, Batin outlined the idea of "distributed organs," where instead of growing an entire organ, individual tissues are tested to see if they can perform a measurable task, such as obtaining a substance from the blood, converting it, and returning the product to the bloodstream. The cells of the liver, for example, produce blood proteins, participate in metabolism, and process medications. Islet cells of the pancreas read glucose levels and secrete insulin. Some of these tasks depend on the complex structure of the organ, including channels, fluid flows, or mechanical movement. Others primarily require access to blood and response to body signals. In his post, Batin formulated the idea as: "To restore organ function, it is not necessary to restore the entire organ." His model first selects one function and measures the additional functional reserve it would give the body. Then, for the module, it is determined what it takes from the blood, what it returns to it, and how it responds to body signals. The condition of the transplanted module must be monitored, and if necessary, it can be removed, as living tissue continues to change after transplantation. Separate elements of this scheme have already been tested, including in an experiment on pigs where their own hepatocytes were introduced into lymph nodes. 🔗 Read original →

LifeMine Funding LifeMine has raised $263 million for LIFE-001, a long-acting injection to protect transplants from rejection. On August 6, the company announced two venture rounds: $75 million in late 2025 and $188 million in a new round. The funds will go towards LIFE-001, a long-acting injection to protect transplanted organs and cells from immune attack. The program is already in its first clinical phase, with plans to research kidney and islet cell transplants next. Transplanting a donor organ or cells is not enough, as the immune system recognizes foreign tissue and sends T-cells to attack. Inflammation damages the transplant, so recipients take immunosuppressive drugs for years, which can create another problem: suppressed immunity and organ toxicity. Calcineurin is an enzyme inside T-cells that signals an immune attack. Common drugs, such as tacrolimus and cyclosporin, suppress this signal through immunophilin proteins. LifeMine is developing LIFE-001 as a long-acting injection, claiming the molecule binds calcineurin at a different site and keeps the enzyme inactive. This idea has a specific route to the clinic, with a first phase registered on ClinicalTrials.gov for 160 healthy adults. The company plans to start a second phase for kidney transplants and a phase Ib for islet cell transplants in early 2027. The funds from the round should finance this transition: from testing doses in healthy volunteers to testing LIFE-001 in people with transplanted tissue. 🔗 Read original →

US Opens AI Model Portal The US Department of Energy opened the Genesis Open Models portal on August 7 to collect contributions for training a future scientific AI model. Universities, national laboratories, companies, and non-profit scientific organizations can submit data, code, models, tests, and working environments. The portal is accepting applications for basic materials until August 14 and for tasks and environments for additional training until August 25. Currently, participants are submitting descriptions of their future contributions and information about them. The scientific task rarely reduces to a question with a ready answer, and researchers often have to choose the next test to conduct, analyze failures, and decide what to do next. In July, the US Department of Energy selected 278 Genesis Mission projects that the program should provide models and calculations for. The new portal is collecting data, tasks, and working environments for training and testing Genesis-Science-1, a future scientific AI model being developed by the US Department of Energy in collaboration with Arcee AI. The model will be trained on working environments with datasets, documentation, tools, journals, partial results, and verification rules, as described in Genesis-Science-1. 🔗 Read original →

Chemotherapy Induces Neuropathy Researchers investigated how paklitaxel and cisplatin cause peripheral neuropathy in mice, leading to nerve damage and altered sensitivity. They also found more senescent fibroblasts in skin biopsies from six patients with neuropathy compared to three control participants. In these models, nerve endings in the skin were damaged, and the enzyme SARM1 was activated, depleting NAD+ and triggering axon degeneration. The authors sought to understand what process triggers SARM1 after chemotherapy. After paklitaxel treatment, signs of senescence appeared in the skin of mice, which were linked to dermal fibroblasts, cells that connect to nerve endings. The researchers then genetically removed these cells, preserving nerve endings and normal sensitivity. In mice lacking SARM1, senescent fibroblasts still appeared after chemotherapy, but innervation and sensitivity were maintained. The authors then investigated how these cells transmit a harmful signal, implicating the MK2 protein in the SASP pathway. When MK2 was inhibited, senescent cells remained, but axons and sensitivity were preserved. The authors suggest that MK2-dependent signals from fibroblasts are an upstream link to SARM1 and nerve damage, as reported in a preprint on bioRxiv on 5 августа. 🔗 Read original →

ICE Buys Shock Gloves The US Immigration and Customs Enforcement agency plans to purchase up to $20 million worth of special gloves called GLove, or Generated Low Output Voltage Emitter. These are ordinary tactical gloves until an officer presses a hidden switch, after which they can deliver a short electric impulse upon contact with a person's skin. The manufacturer describes the effect as "sharp, instantaneous, similar to a bee sting" and claims that the stimulation usually leads to cessation of resistance in under three seconds, without burns or marks. The device is integrated into the glove, does not require a separate instrument, operates covertly, and is activated with a single motion. In normal mode, it is just a glove, but in electric mode, it is a control tool that uses a low-voltage impulse for brief painful distraction. Inside, there is a miniature low-voltage generator, contact plates, and a circuit that only triggers upon direct skin contact. This is not a weapon, but rather a "stimulator" designed for a brief pain signal. GLove is an example of how equipment elements are turning into wearable devices with active functionality, almost like early versions of augmentations from science fiction, as described in undisclosed research publications. Miniature electronics, covert activation, instantaneous effect, and lack of marks all make the technology resemble the first steps towards "smart" equipment that expands human capabilities. 🔗 Read original →

Cell Signal Recorder A new system that records cellular signals in natural DNA repeats has been reported on the bioRxiv preprint site on 7 August. The system distinguished four pre-set levels of signal by reading the trace in individual human cells in culture, and accumulated activity traces in mouse tissues over weeks. Brief cellular signals are difficult to capture, as they change rapidly and cells in each sample cannot be measured again after sampling. The molecular recorder works by linking a chosen signal to a DNA editor beforehand; when the signal arises, the editor leaves small changes in the DNA that can be read by sequencing. In 2016, Reza Kalhor and colleagues created a changing DNA barcode that recorded cellular history in one genomic locus. A guiding RNA led the Cas9 protein to the site where the same instruction was recorded. However, one locus contains limited distinguishable information, so previous systems had to reconstruct signal history from many cells. The authors of the new work use natural genomic repeats, with one guiding RNA leading the editor to hundreds of similar sites, and a single pair of primers allowing them to be read by sequencing. In the human prototype, 304 sites were read, with 234 distinguishable by sequence. Each copy responds to one signal at its own rate, with fast sites distinguishing short exposures and saturating earlier, and slow sites preserving differences with long exposure. The combination of all changes therefore carries information about both signal strength and duration. When the authors applied four levels of controlling signal to cells, this set of changes allowed correct identification of the previous level in 640 out of 747 individual cells, or 85.7% of cases. For comparison, sites with one or two copies gave around a third of correct answers. For the mouse experiment, researchers chose a repeat with 188 copies and made it so that the inclusion of Fos and Npas4 - genes that are quickly activated after cell excitation - triggered the guiding RNA recorder. Over three and ten weeks, the recorder accumulated different traces in the liver, cortex, hippocampus, thalamus, and cerebellum. In an epilepsy seizure model, the Fos recorder registered more editing in the cortex over four weeks; analysis of individual sites revealed differences in the cortex and cerebellum, as reported in bioRxiv, August 2023. 🔗 Read original →

Remedium Bio Funding Remedium Bio closed an investment round Series A for $10 million to develop a therapy where fat cells produce a protein. On August 10, Lifespan Vision Ventures announced the initial closure of the $10 million Series A round for Remedium Bio. The funds will be used to develop therapeutic programs, expand the technology, and prepare for the first clinical trials involving humans. The company is developing a system where a DNA instruction is introduced into subcutaneous fat tissue, and the cells produce the necessary therapeutic protein. After such an injection, it is necessary to be able to reduce protein production. The Prometheus system delivers plasmid DNA, a small ring-shaped molecule with a genetic instruction, to fat cells in lipid nanoparticles, which carry the cargo inside the cell. In a 2024 article, this construct reached approximately four out of five primary human fat cells in culture. In mice, protein production in subcutaneous tissue at the injection site was maintained for six months. The authors also affected the cells in this area. In mouse experiments, cryolipolysis, controlled cooling of fat tissue, and focused ultrasound reduced protein production. In another variant, a built-in genetic switch iCasp9 after drug administration triggered cell death with DNA and also reduced production. After injection, a site remains that can be affected to reduce protein production. The published results were obtained in cell culture and in mice. The new round of funding finances the transition to the first clinical trials of this system, as reported in Nature Aging, July 2026. 🔗 Read original →